Northwest Biotherapeutics signs MOU with Saudi drugmaker SPIMACO to bring DCVax-L to Saudi Arabia

• Northwest Biotherapeutics signed a non-binding MOU with Saudi drugmaker SPIMACO to pursue approval and commercialization of DCVax-L for glioblastoma in Saudi Arabia.
• SPIMACO would lead engagement with the Saudi Food and Drug Authority, marketing, sales, distribution under a revenue-sharing model; NWBio would supply product, regulatory materials.
• Parties plan to negotiate a license and technology transfer to enable localized DCVax-L manufacturing in Saudi Arabia under Vision 2030.
• Collaboration could expand to additional DCVax-L indications or other territories, including Gulf Cooperation Council countries.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Northwest Biotherapeutics Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.